Fairvalue-Calculator Fairvalue-Calculator
EN DE

Harbin Medisan Pharmaceutical Co (002900) Fair Value & Analysis

Healthcare · CN · Market cap 3.1B CNY

Price¥9.85
Fair Value¥3.76
Upside-61.8%
Quality95/100
Evidence: Low Range ¥3.41 – ¥4.30

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Harbin Medisan Pharmaceutical Co (002900) currently trades at ¥9.85, while our model-based Fair Value estimate is ¥3.76 — implying the stock looks roughly 61.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides medical devices and cosmetics. Harbin Medisan Pharmaceutical Co., Ltd. was founded in 1996 and i…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Harbin Medisan Pharmaceutical Co (002900) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥3.76 versus a price of ¥9.85 — about −62% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002900?
Our 21-model fair value for Harbin Medisan Pharmaceutical Co is ¥3.76 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥9.85.
What is the quality score of 002900?
Harbin Medisan Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.